title: Pharmacogenomics in the development and characterization of atheroprotective drugs.
abstract: Atherosclerosis is the main cause of cardiovascular disease (CVD) and can lead to stroke, myocardial infarction, and death. The clinically available atheroprotective drugs aim mainly at reducing the levels of circulating low-density lipoprotein (LDL), increasing high-density lipoprotein (HDL), and attenuating inflammation. However, the cardiovascular risk remains high, along with morbidity, mortality, and incidence of adverse drug events. Pharmacogenomics is increasingly contributing towards the characterization of existing atheroprotective drugs, the evaluation of novel ones, and the identification of promising, unexplored therapeutic targets, at the global molecular pathway level. This chapter presents highlights of pharmacogenomics investigations and discoveries that have contributed towards the elucidation of pharmacological atheroprotection, while opening the way to new therapeutic approaches.
authors.affiliation: Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Athens, 115 27, Greece.
authors.forename: Efi
authors.initials: E
authors.lastname: Valanti
authors.forename: Alexandros
authors.initials: A
authors.lastname: Tsompanidis
authors.forename: Despina
authors.initials: D
authors.lastname: Sanoudou
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D055808:Drug Discovery; D058607:Fibric Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010597:Pharmacogenetics
chemical_list: D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors